Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
Open Access
- 17 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Ovarian Research
- Vol. 13 (1), 1-8
- https://doi.org/10.1186/s13048-020-00629-4
Abstract
Background Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has proven to be effective and safe as maintenance therapy and multiline therapy in ovarian cancer, especially in patients with BRCA mutations. This study intended to observe the influence of tumor load on the efficacy and safety of olaparib in recurrent ovarian cancer. Cases presentation Three patients harbored gBRCAwt with low tumor load (LTL), while two women harbored BRCAmt with high tumor load (HTL) were recruited. Two of the three LTL patients achieved partial response, and the other showed stable disease. Both HTL patients were assessed to have progressive disease in a short time. Olaparib appears to be effective and safe for LTL recurrent ovarian cancer patients even if it is gBRCAwt, while the response is poor in HTL patients. Conclusions Tumor load may be another potential marker to predict the effect of PARP inhibitors. The present head-to-head observational series provides new evidence on this issue for further research from bench to bedside in the future.Funding Information
- Innovative Research Group Project of the National Natural Science Foundation of China (81472441)
This publication has 29 references indexed in Scilit:
- Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future DirectionsCurrent Medicinal Chemistry, 2017
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerThe New England Journal of Medicine, 2016
- Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 MutationJournal of Clinical Oncology, 2015
- “Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?Gynecologic Oncology, 2014
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian CancerThe New England Journal of Medicine, 2012
- Therapeutic strategies in epithelial ovarian cancerJournal of Experimental & Clinical Cancer Research, 2012
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerThe New England Journal of Medicine, 2010
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break RepairJournal of Clinical Oncology, 2008
- Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesisGynecologic Oncology, 2003
- Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity.2000